Masashi Chonan1, Ryuta Saito1, Takuhiro Shoji1, Ichiyo Shibahara1, Masayuki Kanamori1, Yukihiko Sonoda1, Mika Watanabe1, Toshiaki Kikuchi1, Naoto Ishii1, Teiji Tominaga1. 1. Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan (M.C., R.S., T.S., I.S., M.K., Y.S., T.T.); Pathological Division, Tohoku University Hospital, Sendai, Japan (M.W.); Departments of Respiratory Oncology and Molecular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (T.K.); Department of Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan (N.I.).
Abstract
BACKGROUND: The prognosis of glioblastoma (GBM) remains poor; therefore, effective therapeutic strategies need to be developed. CD40 is a costimulatory molecule whose agonistic antibody has been shown to activate antitumor effects. Recently, CD40 has been extensively targeted for immunotherapeutic purposes. METHODS: Expressions of CD40/CD40L mRNAs were examined in 86 cases of World Health Organization grade IV GBM and 36 cases of grade III gliomas and correlated with outcomes. CD40 signaling was employed to augment the efficacy of immunotherapy against gliomas. The efficacy of FGK45, an agonistic antibody for CD40, was examined by adding it to a tumor lysate-based subcutaneous vaccination against a GL261 glioma model and an NSCL61 glioma-initiating cell-like cell tumor model. RESULTS: We demonstrated for the first time using quantitative PCR that grade III gliomas express higher levels of CD40/CD40L than does grade IV GBM. The higher expression of CD40/CD40L was associated with good prognoses in patients with GBM. Addition of FGK45 to the subcutaneous tumor cell lysate-based vaccination significantly prolonged survival in both tumor models. However, the efficacy was modest in NSCL61-model mice. Therefore, we established combination immunotherapeutic strategies using FGK45 and OX86, an agonistic antibody for OX40. Combination immunotherapy significantly prolonged survival with synergistic effects. Apoptosis increased and proliferation decreased in tumors treated with combination immunotherapy. CONCLUSIONS: The high expression of CD40/CD40L can be used as a biomarker for better prognoses in patients with gliomas. Immunotherapy using FGK45 significantly prolonged survival and represents a potential therapeutic strategy for gliomas including glioma-initiating cells.
BACKGROUND: The prognosis of glioblastoma (GBM) remains poor; therefore, effective therapeutic strategies need to be developed. CD40 is a costimulatory molecule whose agonistic antibody has been shown to activate antitumor effects. Recently, CD40 has been extensively targeted for immunotherapeutic purposes. METHODS: Expressions of CD40/CD40L mRNAs were examined in 86 cases of World Health Organization grade IV GBM and 36 cases of grade III gliomas and correlated with outcomes. CD40 signaling was employed to augment the efficacy of immunotherapy against gliomas. The efficacy of FGK45, an agonistic antibody for CD40, was examined by adding it to a tumor lysate-based subcutaneous vaccination against a GL261 glioma model and an NSCL61 glioma-initiating cell-like cell tumor model. RESULTS: We demonstrated for the first time using quantitative PCR that grade III gliomas express higher levels of CD40/CD40L than does grade IV GBM. The higher expression of CD40/CD40L was associated with good prognoses in patients with GBM. Addition of FGK45 to the subcutaneous tumor cell lysate-based vaccination significantly prolonged survival in both tumor models. However, the efficacy was modest in NSCL61-model mice. Therefore, we established combination immunotherapeutic strategies using FGK45 and OX86, an agonistic antibody for OX40. Combination immunotherapy significantly prolonged survival with synergistic effects. Apoptosis increased and proliferation decreased in tumors treated with combination immunotherapy. CONCLUSIONS: The high expression of CD40/CD40L can be used as a biomarker for better prognoses in patients with gliomas. Immunotherapy using FGK45 significantly prolonged survival and represents a potential therapeutic strategy for gliomas including glioma-initiating cells.
Authors: Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis Journal: N Engl J Med Date: 2006-08-14 Impact factor: 91.245
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Wojciech K Panek; Katarzyna C Pituch; Jason Miska; Julius W Kim; Aida Rashidi; Deepak Kanojia; Aurora Lopez-Rosas; Yu Han; Dou Yu; Catalina Lee Chang; J Robert Kane; Peng Zhang; Alex Cordero; Maciej S Lesniak Journal: Mol Neurobiol Date: 2018-11-20 Impact factor: 5.590
Authors: Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai Journal: J Neurooncol Date: 2018-10-23 Impact factor: 4.130
Authors: Luuk van Hooren; Alessandra Vaccaro; Mohanraj Ramachandran; Konstantinos Vazaios; Sylwia Libard; Tiarne van de Walle; Maria Georganaki; Hua Huang; Ilkka Pietilä; Joey Lau; Maria H Ulvmar; Mikael C I Karlsson; Maria Zetterling; Sara M Mangsbo; Asgeir S Jakola; Thomas Olsson Bontell; Anja Smits; Magnus Essand; Anna Dimberg Journal: Nat Commun Date: 2021-07-05 Impact factor: 14.919